为癌症治疗利用翻译机器:翻译因素作为有希望的目标
1Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
International journal of molecular sciences
|October 16, 2024
概括
最近研究真核蛋白转化方面的进展揭示了其治疗潜力. 向转化因子为开发新型癌症化疗药物提供了新的策略,通过抑制癌细胞中的蛋白质合成.
科学领域:
- 分子生物学分子生物学
- 生物化学 生物化学
- 在瘤学瘤学.
背景情况:
- 细胞蛋白转化,一个基本的生物过程,越来越多地被认为是其治疗潜力.
- 最近的技术进步显著加深了我们对核糖体功能和全球翻译的理解.
- 失调的蛋白质翻译是瘤发生的关键驱动因素,因为快速分裂的癌细胞严重依赖蛋白质合成.
研究的目的:
- 审查转化因子在癌症进展和瘤发生中的关键作用.
- 探索针对癌症治疗的转化因子的治疗潜力.
- 突出转化因子作为有希望的药物点的演变.
主要方法:
- 关于真核体翻译研究的综合文献综述.
- 分析转化因子在癌症发展中的参与.
- 检查针对转化因子的基于小分子的策略.
主要成果:
- 翻译因子对于维持蛋白质合成平衡至关重要,并且在癌症中经常异常表达.
- 向转化因子可以以基因特定的方式抑制蛋白质合成.
- 针对转化因子的小分子显示出开发新型癌症治疗方法的前景.
结论:
- 转化因子是瘤发生的核心,是癌症治疗的可行标.
- 准真核蛋白转化机制为新型化疗药物开发提供了一个有前途的途径.
- 对转化因子的进一步研究可能会导致各种癌症类型的创新治疗方法.
相关概念视频
Translation
141.6K
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
141.6K
Leaky Scanning
5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K
Initiation of Translation
31.5K
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
31.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Improving Translational Accuracy
9.3K
Base complementarity between the three base pairs of mRNA codon and the tRNA anticodon is not a failsafe mechanism. Inaccuracies can range from a single mismatch to no correct base pairing at all. The free energy difference between the correct and nearly correct base pairs can be as small as 3 kcal/ mol. With complementarity being the only proofreading step, the estimated error frequency would be one wrong amino acid in every 100 amino acids incorporated. However, error frequencies observed in...
9.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


